Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

Detalles Bibliográficos
Autores principales: Zingone, Fabiana, Buda, Andrea, Savarino, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2020
Materias:
Correspondence`
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547636/
https://www.ncbi.nlm.nih.gov/pubmed/33051162
http://dx.doi.org/10.1016/j.dld.2020.09.020
_version_ 1783592462643625984
author Zingone, Fabiana
Buda, Andrea
Savarino, Edoardo
author_facet Zingone, Fabiana
Buda, Andrea
Savarino, Edoardo
author_sort Zingone, Fabiana
collection PubMed
description
format Online
Article
Text
id pubmed-7547636
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75476362020-10-13 Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice Zingone, Fabiana Buda, Andrea Savarino, Edoardo Dig Liver Dis Correspondence` Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2020-11 2020-10-10 /pmc/articles/PMC7547636/ /pubmed/33051162 http://dx.doi.org/10.1016/j.dld.2020.09.020 Text en © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence`
Zingone, Fabiana
Buda, Andrea
Savarino, Edoardo
Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title_full Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title_fullStr Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title_full_unstemmed Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title_short Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
title_sort reply to comment: asymptomatic screening for sars cov-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
topic Correspondence`
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547636/
https://www.ncbi.nlm.nih.gov/pubmed/33051162
http://dx.doi.org/10.1016/j.dld.2020.09.020
work_keys_str_mv AT zingonefabiana replytocommentasymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice
AT budaandrea replytocommentasymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice
AT savarinoedoardo replytocommentasymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice

Ejemplares similares